Description

1. Overview

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH). It has primarily been investigated for neurological, cognitive, and neuroprotective effects. Semax has a history of clinical use in Russia, but it is not FDA-approved in the United States. FDA has identified concerns regarding potential immunogenicity and peptide-related impurities.

2. Potential Benefits Under Research

Research has investigated Semax for:

• Cognitive function and attention
• Neuroprotective effects
• Recovery following ischemic stroke
• Brain injury and neurological conditions
• Neuroplasticity-related pathways
• BDNF and other neurotrophic signaling

Most published clinical evidence comes from Russian studies, with limited independent replication in Western clinical trials. These findings should therefore be considered investigational rather than established benefits.

3. How It Works

Semax is thought to influence several neurological signaling pathways, including pathways associated with neurotrophic factors, neurotransmitter systems, and cellular stress responses. Its precise mechanism in humans has not been fully established.

4. Semax 10 mg

10 mg refers to the stated quantity of Semax in a particular product. It should not automatically be interpreted as an established therapeutic dose. Published human research has primarily investigated intranasal administration, and there is insufficient evidence to establish a standardized 10 mg regimen for general use.

5. Possible Side Effects & Risks

Available human safety information is limited. Reported or potential concerns include:

• Nasal irritation with intranasal administration
• Headache
• Possible changes in blood pressure
• Hypersensitivity reactions
• Unknown long-term effects
• Potential immunogenicity and peptide-related impurities

FDA has noted limited safety information for Semax and specifically raised concerns about immunogenicity related to aggregation and peptide impurities.

6. Regulatory Status

Semax is not FDA-approved for any medical indication in the United States. Its clinical research history is primarily associated with Russia, and the quality of evidence varies substantially between studies.

7. Conclusion

Semax 10 mg is best described as an investigational neuroactive peptide. Research has explored its potential effects on cognition, neurological recovery, and neuroprotective pathways, but the available evidence is not sufficient to establish a standardized 10 mg treatment or broad medical indications.